Literature DB >> 27479826

Significant functional difference between TNFAIP3 truncation and missense mutants.

Leire Escudero-Ibarz1, Ming Wang1, Ming-Qing Du2.   

Abstract

Entities:  

Keywords:  NF-κB activation; TNFAIP3 mutation

Mesh：

Substances：

Year:  2016        PMID： 27479826      PMCID： PMC5060036          DOI： 10.3324/haematol.2016.148346

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  16 in total

1.  The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas.

Authors:  Urban Novak; Andrea Rinaldi; Ivo Kwee; Subhadra V Nandula; Paola M V Rancoita; Mara Compagno; Michaela Cerri; Davide Rossi; Vundavalli V Murty; Emanuele Zucca; Gianluca Gaidano; Riccardo Dalla-Favera; Laura Pasqualucci; Govind Bhagat; Francesco Bertoni
Journal:  Blood       Date:  2009-03-03       Impact factor: 22.113

Review 2.  A20: central gatekeeper in inflammation and immunity.

Authors:  Beatrice Coornaert; Isabelle Carpentier; Rudi Beyaert
Journal:  J Biol Chem       Date:  2008-11-13       Impact factor: 5.157

3.  A20 is targeted by promoter methylation, deletion and inactivating mutation in MALT lymphoma.

Authors:  E Chanudet; Y Huang; K Ichimura; G Dong; R A Hamoudi; J Radford; A C Wotherspoon; P G Isaacson; J Ferry; M-Q Du
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

4.  KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype.

Authors:  A Clipson; M Wang; L de Leval; M Ashton-Key; A Wotherspoon; G Vassiliou; N Bolli; C Grove; S Moody; L Escudero-Ibarz; G Gundem; K Brugger; X Xue; E Mi; A Bench; M Scott; H Liu; G Follows; E F Robles; J A Martinez-Climent; D Oscier; A J Watkins; M-Q Du
Journal:  Leukemia       Date:  2014-11-27       Impact factor: 11.528

5.  Somatic Mutation Screening Using Archival Formalin-Fixed, Paraffin-Embedded Tissues by Fluidigm Multiplex PCR and Illumina Sequencing.

Authors:  Ming Wang; Leire Escudero-Ibarz; Sarah Moody; Naiyan Zeng; Alexandra Clipson; Yuanxue Huang; Xuemin Xue; Nicholas F Grigoropoulos; Sharon Barrans; Lisa Worrillow; Tim Forshew; Jing Su; Andrew Firth; Howard Martin; Andrew Jack; Kim Brugger; Ming-Qing Du
Journal:  J Mol Diagn       Date:  2015-07-09       Impact factor: 5.568

6.  Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation.

Authors:  Fuminori Tokunaga; Hiroshi Nishimasu; Ryuichiro Ishitani; Eiji Goto; Takuya Noguchi; Kazuhiro Mio; Kiyoko Kamei; Averil Ma; Kazuhiro Iwai; Osamu Nureki
Journal:  EMBO J       Date:  2012-08-28       Impact factor: 11.598

7.  TNFAIP3/A20 functions as a novel tumor suppressor gene in several subtypes of non-Hodgkin lymphomas.

Authors:  Keiichiro Honma; Shinobu Tsuzuki; Masao Nakagawa; Hiroyuki Tagawa; Shigeo Nakamura; Yasuo Morishima; Masao Seto
Journal:  Blood       Date:  2009-07-16       Impact factor: 22.113

8.  Frequent inactivation of A20 in B-cell lymphomas.

Authors:  Motohiro Kato; Masashi Sanada; Itaru Kato; Yasuharu Sato; Junko Takita; Kengo Takeuchi; Akira Niwa; Yuyan Chen; Kumi Nakazaki; Junko Nomoto; Yoshitaka Asakura; Satsuki Muto; Azusa Tamura; Mitsuru Iio; Yoshiki Akatsuka; Yasuhide Hayashi; Hiraku Mori; Takashi Igarashi; Mineo Kurokawa; Shigeru Chiba; Shigeo Mori; Yuichi Ishikawa; Koji Okamoto; Kensei Tobinai; Hitoshi Nakagama; Tatsutoshi Nakahata; Tadashi Yoshino; Yukio Kobayashi; Seishi Ogawa
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

9.  Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

Authors:  Mara Compagno; Wei Keat Lim; Adina Grunn; Subhadra V Nandula; Manisha Brahmachary; Qiong Shen; Francesco Bertoni; Maurilio Ponzoni; Marta Scandurra; Andrea Califano; Govind Bhagat; Amy Chadburn; Riccardo Dalla-Favera; Laura Pasqualucci
Journal:  Nature       Date:  2009-05-03       Impact factor: 49.962

Review 10.  A20 in inflammation and autoimmunity.

Authors:  Leen Catrysse; Lars Vereecke; Rudi Beyaert; Geert van Loo
Journal:  Trends Immunol       Date:  2013-11-15       Impact factor: 16.687
View more
  5 in total

1.  Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma.

Authors:  Christian Grommes; Sarah S Tang; Julia Wolfe; Thomas J Kaley; Mariza Daras; Elena I Pentsova; Anna F Piotrowski; Jacqueline Stone; Andrew Lin; Craig P Nolan; Malbora Manne; Paolo Codega; Carl Campos; Agnes Viale; Alissa A Thomas; Michael F Berger; Vaios Hatzoglou; Anne S Reiner; Katherine S Panageas; Lisa M DeAngelis; Ingo K Mellinghoff
Journal:  Blood       Date:  2018-12-19       Impact factor: 22.113

2.  Functional analysis of novel A20 variants in patients with atypical inflammatory diseases.

Authors:  Saori Kadowaki; Kunio Hashimoto; Toyoki Nishimura; Kenichi Kashimada; Tomonori Kadowaki; Norio Kawamoto; Kohsuke Imai; Satoshi Okada; Hirokazu Kanegane; Hidenori Ohnishi
Journal:  Arthritis Res Ther       Date:  2021-02-06       Impact factor: 5.156

Review 3.  A20 Haploinsufficiency in East Asia.

Authors:  Tomonori Kadowaki; Saori Kadowaki; Hidenori Ohnishi
Journal:  Front Immunol       Date:  2021-11-26       Impact factor: 7.561

4.  CCR6 activation links innate immune responses to mucosa-associated lymphoid tissue lymphoma development.

Authors:  Boguslawa Korona; Dagmara Korona; Wanfeng Zhao; Andrew C Wotherspoon; Ming-Qing Du
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

Review 5.  Chromosomal abnormalities related to fever of unknown origin in a Chinese pediatric cohort and literature review.

Authors:  Bijun Sun; Mi Yang; Jia Hou; Wenjie Wang; Wenjing Ying; Xiaoying Hui; Qinhua Zhou; Haili Yao; Jinqiao Sun; Xiaochuan Wang
Journal:  Orphanet J Rare Dis       Date:  2022-07-27       Impact factor: 4.303
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.